The Single-dose Antibiotic
Researchers at Duke University led a study which could potentially change the future of bacterial skin infection treatments. The study involved the use of oritavancin, a new antibiotic administered as a large, single infusion to patients with acute bacterial skin infections. A control group received the current treatment, which involved two daily infusions of antibiotics over the course of 10 days. The results showed that both treatments were just as effective in reducing skin lesions and fevers without the need for additional antibiotics.
Often, patients do not complete their full 10-day treatment even after their symptoms disappear, allowing surviving strains of bacteria to become more resistant to antibiotics. Since oritavancin can persist in the body for longer periods of time, the use of a single-dose therapy can provide easier treatment options which can help reduce the recurrence of antibiotic-resistant bacteria.